Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2013

Chapman Paul B

Abstract excerpt

Treatment of V600E/K BRAF-mutated melanomas with RAF inhibitors (either vemurafenib or dabrafenib) results in rapid and dramatic responses in most patients-results that are associated with improved progression-free survival (PFS) and in the case of vemurafenib, overall survival (OS). However, res...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Feedback, Physiological
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to MAP Kinase Signaling System

Share to Oximes

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23714462
DOI: 10.14694/EdBook_AM.2013.33.e80

Genes

BRAF
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23714462-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.PMID 23714462Read ↗

Resistance to BRAF-targeted therapy in melanoma.Semantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

Tumor adaptation and resistance to RAF inhibitors.Semantic proximity Read ↗

Adaptive resistance to <scp>RAF</scp> inhibitors in melanomaSemantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.Semantic proximity Read ↗

MAPK pathway inhibition in melanoma: resistance three waysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.